Pfizer-BioNTech announced on Monday that its two-dose COVID-19 vaccine was found to be safe and showed “robust” antibody response in children ages 5 to 11, according to a press readout.

Data was gathered throughout the test trials on more than 2,000 children. German partner BioNTech described the vaccine’s use in the age group as “safe, well-tolerated, and showed robust neutralizing antibody responses.”